Evotec SE (EVO) EBIT Margin (2009 - 2025)

Evotec SE (EVO) posted EBIT Margin of 14.92% for Q4 2025, up 154.96% sequentially from 27.15% in Q3 2025, and up 1239.0% YoY from 1.11% in Q4 2024.

Evotec SE (EVO) EBIT Margin (2009 - 2025) Analysis & Trends

Evotec SE has reported EBIT Margin for 9 years, with the latest figure at 14.92% in Q4 2025.

Quarterly EBIT Margin rose 1239.0% year-over-year to 14.92% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3.36% (up 44.0% YoY) and the FY2025 annual result came in at 9449.52%, down 943164.0% from the prior year.
EBIT Margin improved to 14.92% in Q4 2025 per EVO's latest filing, from 27.15% in the prior quarter.
Over five years, EBIT Margin peaked at 38.98% in Q1 2021 and troughed at 27.15% in Q3 2025.
A 5-year average of 4.07% and a median of 4.9% in 2021 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2021 and 2025: EBIT Margin sank 4013 bps in 2021, then soared 1239 bps in 2025.
Over 5 years, EBIT Margin stood at 6.05% in 2021, then slumped by 155 bps to 3.3% in 2022, then tumbled by 88 bps to 6.2% in 2023, then soared by 141 bps to 2.53% in 2024, then surged by 489 bps to 14.92% in 2025.
According to Business Quant data, EBIT Margin over the past three periods registered 14.92%, 27.15%, and 2.53% for Q4 2025, Q3 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Haleon	44.36 Bn	43.40 Bn	-	-
2	Teva Pharmaceutical Industries	43.73 Bn	40.08 Bn	2.15 Bn	-5.58%
3	Zoetis	32.52 Bn	30.84 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.14 Bn	19.48 Bn	683.80 Mn	42.23%
6	Viatris	18.93 Bn	18.04 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.49 Bn	15.10 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	12.00 Bn	11.47 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.15 Bn	9.98 Bn	-	-
10	Evotec SE	692.56 Mn	692.08 Mn	-	-

Download Data